Novartis Acquires Tourmaline Bio for Cardio Breakthroughs

Novartis has formally closed its acquisition of Tourmaline Bio, a strategic step to advance its leadership in cardiovascular innovation.

After the closing, common stock of Tourmaline, with each share having a par value of $0.0001, has ceased trading on the Nasdaq Stock Market. The company is now an indirect wholly owned subsidiary of Novartis.

This deal reflects Novartis' continuous business approach to growth in areas of therapy where it can lead with science and provide sustained value. The acquisition solidifies the company's commitment to developing revolutionary solutions for cardiovascular disease, said Shreeram Aradhye, M.D., President of Development and Chief Medical Officer, Novartis.

Also Read: India's Innovative Therapies Set Global Standard at Low Cost

One of the key strengths of this deal is Pacibekitug, Tourmaline's novel anti-IL-6 therapy. The differentiated mechanism of the drug addresses residual inflammation — an important driver of atherosclerotic cardiovascular disease (ASCVD). This addition will help Novartis build its cardiovascular portfolio and move therapies forward that have the potential to transform treatment strategies for tens of millions of patients globally.

Aradhye emphasized that Novartis is eager to work with Tourmaline’s team to further develop Pacibekitug and speed up research in cardiovascular innovation. This effort supports Novartis’ larger goal of tackling diseases with significant unmet medical needs and strengthening its position in the global biopharmaceutical field. Completing the Tourmaline Bio acquisition is another important step in Novartis’ mission to change cardiovascular care through leading science and strategic partnerships.